Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study

Background: Trastuzumab emtansine (T-DM1) has demonstrated improvements in survival and neurological symptoms in patients with breast cancer with brain metastases (BCBM). This real-world study investigated the effectiveness of T-DM1 versus lapatinib plus capecitabine (LC) in patients with BCBM. Meth...

Full description

Bibliographic Details
Main Authors:	Thibaut Sanglier, Jinjoo Shim, Neil Lamarre, Claudia Peña-Murillo, Vincent Antao, Filippo Montemurro
Format:	Article
Language:	English
Published:	Elsevier 2023-06-01
Series:	Breast
Subjects:	Trastuzumab emtansine HER2-Positive metastatic breast cancer Brain metastases Lapatinib plus capecitabine Real-world
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977623000073

Similar Items

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
by: Alexey A. Larionov
Published: (2018-04-01)

Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease
by: Lauren Ogawa, et al.
Published: (2018-12-01)

T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer
by: Thibaut Sanglier, et al.
Published: (2022-05-01)

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
by: Recondo G Jr, et al.
Published: (2016-05-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
by: Alessandro D. Santin, et al.
Published: (2017-02-01)

Efficacy and safety of trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer: a single center study
by: Eyyup Cavdar, et al.
Published: (2022-08-01)

Lapatinib and capecitabine as third-line therapy in young woman with advanced breast cancer
by: Michela Donadio
Published: (2018-06-01)

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
by: Tatiana Strava Corrêa, et al.
Published: (2018-05-01)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022-09-01)

Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
by: Kazuki Nozawa, et al.
Published: (2022-09-01)

Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea
by: Ro Jungsil, et al.
Published: (2012-07-01)

Efficacia duratura e ottima tollerabilità di lapatinib associato a capecitabina metronomica in due pazienti con carcinoma mammario HER2-positivo
by: Armando Orlandi, et al.
Published: (2017-12-01)

Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation
by: Mark Barok, et al.
Published: (2018-05-01)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
by: Hiromichi Nakajima, et al.
Published: (2022-02-01)

Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine
by: Audrey Mailliez, et al.
Published: (2014-08-01)

All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer – A phase II study
by: Hanan Shawky, et al.
Published: (2014-12-01)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
by: Julie Lebert, et al.
Published: (2022-04-01)

The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
by: Peipei Liu, et al.
Published: (2020-06-01)

Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
by: Fan Yang, et al.
Published: (2020-03-01)

Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine
by: İzzet Doğan, et al.
Published: (2023-04-01)

Efficacy of lapatinib-capecitabine combination in a patient with multiple metastasis from HER2-positive breast cancer
by: Maria Moritti, et al.
Published: (2018-06-01)

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial
by: Elena López-Miranda, et al.
Published: (2020-11-01)

Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2022-12-01)

Efficacia della combinazione lapatinib-capecitabina in una paziente con carcinoma mammario HER2-positivo metastatico e con resistenza primaria a due linee di terapia con agenti anti-HER2
by: Claudio Vernieri, et al.
Published: (2017-12-01)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
by: Ye Yuan, et al.
Published: (2022-12-01)

Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
by: Marcos Aurélio Fonseca Magalhães Filho, et al.
Published: (2022-05-01)

Safety and efficacy of trastuzumab emtansine (TDM-1) in a patient on hemodialysis for renal failure
by: A. Falcón González, et al.
Published: (2021-01-01)

Dose-Reduced Trastuzumab Emtansine: Active and Safe in Acute Hepatic Dysfunction
by: Adam Sharp, et al.
Published: (2015-02-01)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
by: Claudia Omarini, et al.
Published: (2022-06-01)

Good control of diffuse brain metastasis with lapatinib plus capecitabine in a patient with HER2-positive breast cancer
by: Giovanni Faggioni
Published: (2018-06-01)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
by: Salkeni MA, et al.
Published: (2021-09-01)

Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report
by: Xiao-Dong Jiao, et al.
Published: (2018-02-01)

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
by: Sanne L. de Haas, et al.
Published: (2023-01-01)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
by: Matthew N. Mills, et al.
Published: (2021-03-01)

Systemic control and encephalic response with lapatinib plus capecitabine as second-line therapy in HER2-positive, metastatic breast cancer
by: Raffaele Ardito, et al.
Published: (2018-09-01)

Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)
by: Takahiro Nakayama, et al.
Published: (2021-07-01)

Toxicity management and efficacy of lapatinib-capecitabine in elderly patient with lymph node metastasis from HER2-positive occult mammary carcinoma
by: Giuseppe Quarta, et al.
Published: (2018-06-01)